NCT00935220 - Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

August 31, 2010

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

linagliptin QD (once daily) for 7 days

dipeptidyl peptidase IV (DPP-4) activity will be measured as PD response to drug administration

Trial Locations (6)

1218.55.0006 Boehringer Ingelheim Investigational Site, Cypress

1218.55.0008 Boehringer Ingelheim Investigational Site, DeLand

1218.55.0004 Boehringer Ingelheim Investigational Site, Miami

1218.55.0005 Boehringer Ingelheim Investigational Site, Baltimore

1218.55.0003 Boehringer Ingelheim Investigational Site, New York

1218.55.0001 Boehringer Ingelheim Investigational Site, Dallas